

Gastroenterology: Hepatitis C - Glecaprevir/Pibrentasvir Order Set

Order Set: Conceptual Structure

Contract: VA118-16-D-1008, Task Order (TO): VA-118-16-F-1008-0007, CLIN0004AF

Department of Veterans Affairs (VA)



**Knowledge Based Systems (KBS)
Office of Informatics and Information Governance (OIIG)
Clinical Decision Support (CDS)**

Publication date 06/14/2018

Version: 1.0

Gastroenterology: Hepatitis C - Glecaprevir/Pibrentasvir Order Set: Order Set: Conceptual Structure

by Knowledge Based Systems (KBS), Office of Informatics and Information Governance (OIIG), and Clinical Decision Support (CDS)

Publication date 06/14/2018

Copyright © 2018 B3 Group, Inc.

Copyright © 2018 Cognitive Medical Systems, Inc.

B3 Group, Inc.

NOTICE OF GOVERNMENT COPYRIGHT LICENSE AND UNLIMITED RIGHTS LICENSE

Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License.

You may obtain a copy of the License at <http://www.apache.org/licenses/LICENSE-2.0>

Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License.

Portions of this content are derivative works from content produced by Cognitive Medical Systems, Inc. licensed under the Apache License, Version 2.0.

Additional portions of this content are derivative works from content contributed by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike 4.0.

Contributions from 2013-2018 were performed either by US Government employees, or under US Veterans Health Administration contracts.

US Veterans Health Administration contributions by government employees are work of the U.S. Government and are not subject to copyright protection in the United States. Portions contributed by government employees are USGovWork (17USC §105). Not subject to copyright.

See: <https://www.usa.gov/government-works>

Contribution by contractors to the US Veterans Health Administration during this period are contractually contributed under the Apache License, Version 2.0 and US Government sponsorship is acknowledged under Contract VA118-16-D-1008, Task Order VA11817F10080007.

Cognitive Medical Systems, Inc.

Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License.

You may obtain a copy of the License at <http://www.apache.org/licenses/LICENSE-2.0>

Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License.

This and related content produced by Cognitive Medical Systems, Inc. licensed under the Apache License, Version 2.0 is available at: <https://bitbucket.org/cogmedsys/hl7-kas-examples>

Additional portions of this content are derivative works from content contributed by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike 4.0. <https://bitbucket.org/cogmedsys/kas-source-material>

Contributions from 2013-2018 were performed either by US Government employees, or under US Veterans Health Administration contracts.

US Veterans Health Administration contributions by government employees are work of the U.S. Government and are not subject to copyright protection in the United States. Portions contributed by government employees are USGovWork (17USC §105). Not subject to copyright. See: <https://www.usa.gov/government-works>

Contribution by contractors to the US Veterans Health Administration during this period are contractually contributed under the Apache License, Version 2.0 and US Government sponsorship is acknowledged under Contract VA118-16-D-1008-0007.

Table of Contents

Preface	v
Artifact Applicability	vi
Models	vii
1. External Data Definitions	1
2. Expression Definitions	2
3. Medications	5
4. Laboratory Tests	7
5. Patient and Caregiver Education	10
6. Tabular List	12
7. Behavior Symbols	14
A. References	16

List of Tables

1. Revision History	v
2. Clinical White Paper Contributors	v
3. Artifact Identifier	v
4. Applicability Foci, Description and Codes	vi
5. Model References	vii
2.1. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine)	2
2.2. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)	2
2.3. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine)	2
2.4. HCV genotype 1 time (routine)	2
2.5. Hepatitis B surface antigen (HBsAg) 1 time (routine)	3
2.6. Hepatitis B core antibody (HBcAb) 1 time (routine)	3
2.7. Hepatitis B surface antibody (HBsAb) 1 time (routine)	3
2.8. Hepatitis A antibody (HAVAb) 1 time (routine)	3
2.9. HCV viral load (quantitative HCV RNA) 1 time (routine)	3
2.10. HIV test 1 time (routine)	4
2.11. Qualitative human chorionic gonadotropin 1 time (routine)	4
6.1. Terminology Versions	12
6.2. Terminology References	12
7.1. Group Organizational Behavior	14
7.2. Group Selection Behavior	14
7.3. Required Behavior	14
7.4. Precheck Behavior	15
7.5. Cardinality Behavior	15
7.6. Item Flags	15
7.7. Read Only Behavior	15

Preface

Table 1. Revision History

Date	Life Cycle Event
June 14, 2018	Published
May 29, 2018	Published
May 29, 2018	Reviewed
August 29, 2017	Pre-published
August 10, 2017	Created

Table 2. Clinical White Paper Contributors

Name	Role	Affiliation
David Kaplan, MD	Author	Staff Physician Gastroenterology Philadelphia, PA, Primary
Timothy Morgan, MD	Author	Long Beach VAMC Physician Long Beach, CA, Secondary
James Wilson, MD	Author	Puget Sound Healthcare System Administrative Specialist Seattle, WA
Jason Dominitz, MD	Author	Puget Sound Healthcare System National Director of Gastroenterology Seattle, WA
Byron Cryer, MD	Author	North Texas VHCS Physician Dallas, TX
Ashley Faulx, MD	Author	Louis Stokes Cleveland DVA Medical Center Med-GI Fellow Cleveland, OH
Lyn Sue Kahng, MD	Author	Jesse Brown VAMC Section Chief, GI Chicago, IL
Heiko Pohl, MD	Author	Physician White River Junction VAMC White River Junction, VT
Aasma Shaukat, MD	Author	Minneapolis VAMC Minneapolis, MN
Walter Smalley, MD	Author	Tennessee Valley HCS Nashville, TN
Pamela (Pam) Belperio	Author	PharmD/Clinical Pharmacist Population Health Services Los Angeles, CA
Lisa Backus	Author	Deputy Chief Consultant Population Health Services Palo Alto, CA

Table 3. Artifact Identifier

Domain	Artifact ID	Name
urn:va.gov:kbs:knart:artifact:r1	34482f34-a4e0-50e6-93ba-13510350fddf	B30

Artifact Applicability

Table 4. Applicability Foci, Description and Codes

Focus	Description	Code System	Code	Value Set	Value Set Version
TargetUser	Primary Care physicians	SNOMED CT	453231000124104 Primary care provider (occupation)	N/A	N/A
TargetUser	Gastroenterologists			N/A	N/A
PatientAgeGroup	Adult patients	SNOMED CT	133936004 Adult (person)	N/A	N/A
ClinicalFocus	Adult outpatients with chronic Hepatitis C infection			N/A	N/A
WorkflowSetting	Routine primary care and gastroenterology			N/A	N/A
ClinicalVenue	Outpatient	SNOMED CT	33022008 Hospital-based outpatient department (environment)	N/A	N/A

Models

Table 5. Model References

Referenced Model	Description
urn:solor.io:anf-model:1.0	VA Analysis Normal Form Model

Chapter 1. External Data Definitions

No externalData expression definitions and no trigger definitions are present.

Chapter 2. Expression Definitions

Table 2.1. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine)

Expression: type=elm:Instance Annotation: Codes: elm:value[elm:Code]: [385644000 Requested (qualifier value)]elm:value[elm:Code]: [[416118004 Administration (procedure)] ->(260686004 Method (attribute))->[129445006 Administration - action (qualifier value)] ->(363701004 Direct substance (attribute))->[Rx;1940703 glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet] ->(410675002 Route of administration (attribute))->[260548002 Oral (qualifier value)]]elm:value[elm:Code]: [421026006 Conventional release oral tablet (dose form)]elm:value[elm:Code]: [50811001 Routine (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]
--

Table 2.2. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)

Expression: type=elm:Instance Annotation: Codes: elm:value[elm:Code]: [385644000 Requested (qualifier value)]elm:value[elm:Code]: [[416118004 Administration (procedure)] ->(260686004 Method (attribute))->[129445006 Administration - action (qualifier value)] ->(363701004 Direct substance (attribute))->[Rx;1940703 glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet] ->(410675002 Route of administration (attribute))->[260548002 Oral (qualifier value)]]elm:value[elm:Code]: [421026006 Conventional release oral tablet (dose form)]elm:value[elm:Code]: [50811001 Routine (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]
--

Table 2.3. Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine)

Expression: type=elm:Instance Annotation: Codes: elm:value[elm:Code]: [385644000 Requested (qualifier value)]elm:value[elm:Code]: [[416118004 Administration (procedure)] ->(260686004 Method (attribute))->[129445006 Administration - action (qualifier value)] ->(363701004 Direct substance (attribute))->[Rx;1940703 glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet] ->(410675002 Route of administration (attribute))->[260548002 Oral (qualifier value)]]elm:value[elm:Code]: [421026006 Conventional release oral tablet (dose form)]elm:value[elm:Code]: [50811001 Routine (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]elm:value[elm:Code]: [258703001 day (qualifier value)]
--

Table 2.4. HCV genotype 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic, dateProperty=dateTime Annotation:
--

Codes: elm:element[elm:Code]: [397662006 |Hepatitis C virus genotype determination (procedure)]
 dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-5 year))
 high: elm:Today()

Table 2.5. Hepatitis B surface antigen (HBsAg) 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic,
 dateProperty=dateTime
 Annotation:
 Codes: elm:element[elm:Code]: [47758006 |Hepatitis B surface antigen measurement (procedure)]
 dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-10 year))
 high: elm:Today()

Table 2.6. Hepatitis B core antibody (HBcAb) 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic,
 dateProperty=dateTime
 Annotation:
 Codes: elm:element[elm:Code]: [59582004 |Hepatitis B core antibody measurement (procedure)]
 dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-10 year))
 high: elm:Today()

Table 2.7. Hepatitis B surface antibody (HBsAb) 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic,
 dateProperty=dateTime
 Annotation:
 Codes: elm:element[elm:Code]: [65911000 |Hepatitis B surface antibody measurement (procedure)]
 dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-10 year))
 high: elm:Today()

Table 2.8. Hepatitis A antibody (HAVAb) 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic,
 dateProperty=dateTime
 Annotation:
 Codes: elm:element[elm:Code]: [697001 |Hepatitis A virus antibody measurement (procedure)]
 dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-10 year))
 high: elm:Today()

Table 2.9. HCV viral load (quantitative HCV RNA) 1 time (routine)

Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic,
 dateProperty=dateTime
 Annotation:
 Codes: elm:element[elm:Code]: [395197008 |Hepatitis C viral load (procedure)]

dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-6 month)) high: elm:Today()
--

Table 2.10. HIV test 1 time (routine)

<p>Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic, dateProperty=dateTime</p> <p>Annotation:</p> <p>Codes: elm:element[elm:Code]: [359796005 Measurement of both Human immunodeficiency virus 1 antibody and Human immunodeficiency virus 2 antibody (procedure)]</p> <p>dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-6 month)) high: elm:Today()</p>

Table 2.11. Qualitative human chorionic gonadotropin 1 time (routine)

<p>Expression: type=elm:Retrieve , dataType=anf:ClinicalStatement, codeProperty=topic, dateProperty=dateTime</p> <p>Annotation:</p> <p>Codes: elm:element[elm:Code]: [386558001 Chorionic gonadotropin, beta-subunit measurement (procedure)]</p> <p>dateRange[elm:Interval] low: elm:Add(elm:Today() elm:Quantity(-2 week)) high: elm:Today()</p>

Chapter 3. Medications

Glecaprevir/pibrentasvir should not be used in patients with decompensated cirrhosis (CTP B or C). Glecaprevir/pibrentasvir should not be used in combination with atazanavir or rifampin. Providers should check <http://www.hep-druginteractions.org>, <https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp>, and/or a pharmacist for additional drug interactions or contraindications before starting glecaprevir/pibrentasvir.

Hep Drug Interactions link [[https://www.hep-druginteractions.org/.](https://www.hep-druginteractions.org/)]

([VA 2017b]) Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the HIV, Hepatitis, and Related Conditions Program in the Office of Specialty Care Services link [<https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp>]

Genotype 1, 2, 3, 4, 5, or 6, Treatment-Naïve, without Cirrhosis.
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine) actionSentence[type=elm:ExpressionRef, classType=] Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine)
Genotype 1, 2, 3, 4, 5, or 6, Treatment-Naïve, with Compensated Cirrhosis (CTP A).
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine) actionSentence[type=elm:ExpressionRef, classType=] Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)
Genotype 1, Treatment-Experienced (NS5A Protease Inhibitor without Prior NS3/4A Protease Inhibitor), without Cirrhosis.
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine) actionSentence[type=elm:ExpressionRef, classType=] Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)
Genotype 1, 2, 4, 5, or 6, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or Sofosbuvir), without Cirrhosis.
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine) actionSentence[type=elm:ExpressionRef, classType=] Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 1 refills (routine)
Genotype 3, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or Sofosbuvir), without Cirrhosis.
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine) actionSentence[type=elm:ExpressionRef, classType=] Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine)
Genotype 1, Treatment-Experienced (NS5A Protease Inhibitor without Prior NS3/4A Protease Inhibitor), with Compensated Cirrhosis (CTP A).
Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine)

<p>actionSentence[type=elm:ExpressionRef, classType=]</p> <p>Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 3 refills (routine)</p> <p>Genotype 1, Treatment-Experienced (NS3/4A Protease Inhibitor without Prior NS5A Protease Inhibitor), with Compensated Cirrhosis (CTP A).</p>
<p># Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p> <p>actionSentence[type=elm:ExpressionRef, classType=]</p> <p>Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p> <p>Genotype 1, 2, 4, 5, or 6, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or Sofosbuvir), with Compensated Cirrhosis (CTP A).</p>
<p># Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p> <p>actionSentence[type=elm:ExpressionRef, classType=]</p> <p>Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p> <p>Genotype 3, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or Sofosbuvir), with Compensated Cirrhosis (CTP A).</p>
<p># Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p> <p>actionSentence[type=elm:ExpressionRef, classType=]</p> <p>Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral, daily, 84 tablets 2 refills (routine)</p>

Chapter 4. Laboratory Tests

Suggested tests for management of hepatitis C

Complete blood count 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 26604007 |Complete blood
count (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Hepatic function panel 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 26958001 |Hepatic function
panel (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

International normalized ratio 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 440685005 |Calculation of
international normalized ratio (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Basic metabolic panel 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 1421000205106 |Basic
metabolic panel (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Glomerular Filtration rate 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 167181009 |Measurement of
renal clearance of creatinine (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

The following lab is recommended if not performed within the previous 5 years.

Condition:elm:Not (elm:Exists(HCV genotype 1 time (routine)))

HCV genotype 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 47758006 |Hepatitis B
surface antigen measurement (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

The following labs are recommended if not performed within the previous 10 years.

Condition:elm:Not (elm:Exists(Hepatitis B surface antigen (HBsAg) 1 time (routine)))

Hepatitis B surface antigen (HBsAg) 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 47758006 |Hepatitis B
surface antigen measurement (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Condition:elm:Not (elm:Exists(Hepatitis B core antibody (HBcAb) 1 time (routine)))

Hepatitis B core antibody (HBcAb) 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 59582004 |Hepatitis B core
antibody measurement (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Condition:elm:Not (elm:Exists(Hepatitis B surface antibody (HBsAb) 1 time (routine)))

Hepatitis B surface antibody (HBsAb) 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 65911000 |Hepatitis B
surface antibody measurement (procedure)|

priority: Precoordinated Expression 50811001 |Routine
(qualifier value)|

Condition:elm:Not (elm:Exists(Hepatitis A antibody (HAVAb) 1 time (routine)))

Hepatitis A antibody (HAVAb) 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression 697001 |Hepatitis A virus antibody measurement (procedure)|

priority: Precoordinated Expression 50811001 |Routine (qualifier value)|

The following lab is recommended if not performed within the previous 6 months.

Condition:elm:Not (elm:Exists(HCV viral load (quantitative HCV RNA) 1 time (routine)))

HCV viral load (quantitative HCV RNA) 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 | Requested (qualifier value)|

topic: Precoordinated Expression 395197008 |Hepatitis C viral load (procedure)|

priority: Precoordinated Expression 50811001 |Routine (qualifier value)|

Condition:elm:Not (elm:Exists(HIV test 1 time (routine)))

HIV test 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 | Requested (qualifier value)|

topic: Precoordinated Expression 359796005 |Measurement of both Human immunodeficiency virus 1 antibody and Human immunodeficiency virus 2 antibody (procedure)|

priority: Precoordinated Expression 50811001 |Routine (qualifier value)|

The following lab is recommended if not performed within the previous 2 weeks.

Condition:elm:Not (elm:Exists(Qualitative human chorionic gonadotropin 1 time (routine)))

Qualitative human chorionic gonadotropin 1 time (routine)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 | Requested (qualifier value)|

topic: Precoordinated Expression 386558001 |Chorionic gonadotropin, beta-subunit measurement (procedure)|

Chapter 5. Patient and Caregiver Education

This section should be available to users in gastroenterology settings and for primary care providers who are referring a patient to gastroenterology for management of hepatitis C

Hepatitis C Information for Veterans

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression TSR-NoCode

([VA 2017d])

Hepatitis C Information for Veterans link [<https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf>]

Chronic Hepatitis C and Alcohol Use

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression TSR-NoCode

([VA 2017e])

Chronic Hepatitis C and Alcohol Use link [<https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp>]

What to Expect Before Your Treatment for Hepatitis C Virus

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression TSR-NoCode

([VA 2017f])

What to Expect Before Your Treatment for Hepatitis C Virus link [<https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp>]

Taking Your Hepatitis C Therapy: Mavyret(TM)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression TSR-NoCode

([VA 2017g])

Taking Your Hepatitis C Therapy: Mavyret(TM) link [<https://www.hepatitis.va.gov/products/patient/sofosbuvir-simeprevir-handouts.asp>]

Managing Side Effects of Mavyret(TM)

actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]

statementType: Precoordinated Expression 385644000 |
Requested (qualifier value)|

topic: Precoordinated Expression TSR-NoCode

([VA 2017h])	Managing Side Effects of Mavyret(TM) link [https://www.hepatitis.va.gov/products/patient/side-effects-handouts.asp]
# Tracking My Hepatitis C Treatment Results	
actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]	statementType: Precoordinated Expression 385644000 Requested (qualifier value) topic: Precoordinated Expression TSR-NoCode
([VA 2017i])	Tracking My Hepatitis C Treatment Results link [https://www.hepatitis.va.gov/products/patient/tracking-chart.asp]
# FAQs about Sustained Virologic Response to Treatment for Hepatitis C	
actionSentence[type=elm:Instance, classType=anf:ClinicalStatement]	statementType: Precoordinated Expression 385644000 Requested (qualifier value) topic: Precoordinated Expression TSR-NoCode
([VA 2017j])	FAQs about Sustained Virologic Response to Treatment for Hepatitis C link [https://www.hepatitis.va.gov/products/patient/sustained-virological-response.asp]

Chapter 6. Tabular List

Terminology Service Request (TSR) Mappings

Table 6.1. Terminology Versions

Name	Identifier	Version
SNOMED CT	2.16.840.1.113883.6.96	United States Edition 20180301

Table 6.2. Terminology References

System	Code	Display Text ^a	References ^b
SNOMED CT	133936004 Adult (person)	Adult patients	1
SNOMED CT	1421000205106 Basic metabolic panel (procedure)	Precoordinated Expression	1
SNOMED CT	167181009 Measurement of renal clearance of creatinine (procedure)	Precoordinated Expression	1
SNOMED CT	258703001 day (qualifier value)	Precoordinated Expression	6
SNOMED CT	26604007 Complete blood count (procedure)	Precoordinated Expression	1
SNOMED CT	26958001 Hepatic function panel (procedure)	Precoordinated Expression	1
SNOMED CT	33022008 Hospital-based outpatient department (environment)	Outpatient	1
SNOMED CT	359796005 Measurement of both Human immunodeficiency virus 1 antibody and Human immunodeficiency virus 2 antibody (procedure)	Precoordinated Expression	2
SNOMED CT	385644000 Requested (qualifier value)	Precoordinated Expression	23
SNOMED CT	386558001 Chorionic gonadotropin, beta-subunit measurement (procedure)	Precoordinated Expression	2
SNOMED CT	395197008 Hepatitis C viral load (procedure)	Precoordinated Expression	2
SNOMED CT	397662006 Hepatitis C virus genotype determination (procedure)	Precoordinated Expression	1

System	Code	Display Text ^a	References ^b
SNOMED CT	421026006 Conventional release oral tablet (dose form)	Precoordinated Expression	3
SNOMED CT	440685005 Calculation of international normalized ratio (procedure)	Precoordinated Expression	1
SNOMED CT	453231000124104 Primary care provider (occupation)	Primary Care physicians	1
SNOMED CT	47758006 Hepatitis B surface antigen measurement (procedure)	Precoordinated Expression	3
SNOMED CT	50811001 Routine (qualifier value)	Precoordinated Expression	15
SNOMED CT	59582004 Hepatitis B core antibody measurement (procedure)	Precoordinated Expression	2
SNOMED CT	65911000 Hepatitis B surface antibody measurement (procedure)	Pretcoordinated Expression	2
SNOMED CT	697001 Hepatitis A virus antibody measurement (procedure)	Precoordinated Expression	2
SNOMED CT	TSR-NoCode ^c	Precoordinated Expression	7
SNOMED CT	[416118004 Administration (procedure)] ->(260686004 Method (attribute))->[129445006 Administration - action (qualifier value)] ->(363701004 Direct substance (attribute))->[Rx;1940703 glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet] ->(410675002 Route of administration (attribute))->[260548002 Oral (qualifier value)]	Postcoordinated Expression	3

^aIf a code is used multiple times in the KNART, only the display text of the first instance is shown.

^bCount of the number of times the given code system and code pair is used in the KNART.

^cTSR-NoCode is a placeholder indicating a code was requested, but was not provided.

Chapter 7. Behavior Symbols

Table 7.1. Group Organizational Behavior

Symbol	Name	Definition
#	Sentence Group	A group of related alternative actions is a sentence group if the item referenced by the action is the same in all the actions, and each action simply constitutes a different variation on how to specify the details for that item. For example, two actions that could be in a SentenceGroup are "aspirin, 500 mg, 2 times per day" and "aspirin, 300 mg, 3 times per day". In both cases, aspirin is the item referenced by the action, and the two actions represent two different options for how aspirin might be ordered for the patient. Note that a SentenceGroup would almost always have an associated selection behavior of "AtMostOne", unless it's a required action, in which case, it would be "ExactlyOne".
#	Logical Group	A group with this behavior logically groups its sub-elements, and may be shown as a visual group to the end user, but it is not required to do so.
➤	Visual Group	Any group marked with this behavior should be displayed as a visual group to the end user.

Table 7.2. Group Selection Behavior

Symbol	Name	Definition
#	Any	Any number of the items in the group may be chosen, from zero to all.
#	All	All the items in the group must be selected as a single unit.
#	AllOrNone	All the items in the group are meant to be chosen as a single unit: either all must be selected by the end user, or none may be selected.
#	ExactlyOne	The end user must choose one and only one of the selectable items in the group. The user may not choose none of the items in the group.
⬠	AtMostOne	The end user may choose zero or at most one of the items in the group.
✱	OneOrMore	The end user must choose a minimum of one, and as many additional as desired.

Table 7.3. Required Behavior

Symbol	Name	Definition
◆	Must	An action with this behavior must be included in the actions processed by the end user; the end user may not choose not to include this action.
◇	Could	An action with this behavior may be included in the set of actions processed by the end user.

Symbol	Name	Definition
➤	MustUnlessDocumented	An action with this behavior must be included in the set of actions processed by the end user, unless the end user provides documentation as to why the action was not included.

Table 7.4. Precheck Behavior

Symbol	Name	Definition
▲	Yes	An action with this behavior is one of the most frequent actions that is, or should be, included by an end user, for the particular context in which the action occurs. The system displaying the action to the end user should consider "pre-checking" such an action as a convenience for the user.
#	No	An action with this behavior is one of the less frequent actions included by the end user, for the particular context in which the action occurs. The system displaying the actions to the end user would typically not "pre-check" such an action.

Table 7.5. Cardinality Behavior

Symbol	Name	Definition
◆	Single	An action with this behavior may only be completed once.
❖	Multiple	An action with this behavior may be repeated multiple times.

Table 7.6. Item Flags

Symbol	Name	Definition
☞	fillIn	This item, in a list entry, allows the user to enter a fill in value that is not present in the set of presented choices.

Table 7.7. Read Only Behavior

Symbol	Name	Definition
#	true	For a particular action or action group, specifies whether the elements are read only.

Appendix A. References

This appendix contains the list of related resources and supporting documents used in creating this KNART.

List of References

Related Resources

[CCWP] *Gastroenterology: Hepatitis C Clinical Content White Paper*

[CSD] *Gastroenterology: Hepatitis C - Glecaprevir/Pibrentasvir Order Set Conceptual Structure Document*

[KVRpt] *Gastroenterology: Hepatitis C - Glecaprevir/Pibrentasvir Order Set KNART Validation Report*

[UL 2018] *University of Liverpool. 2018. Hep Drug Interactions. Accessed April 25, 2018 from <https://www.hep-druginteractions.org/>. (link [<https://www.hep-druginteractions.org/>])*

[VA 2017d] *US Dept of Veterans Affairs. 2017. Hepatitis C Information for Veterans. Accessed April 25, 2018 from <https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf>. (link [<https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf>])*

[VA 2017e] *US Dept of Veterans Affairs. Chronic Hepatitis C and Alcohol Use. 2017. [Internet]. Accessed April 25, 2018 from <https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp>. (link [<https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp>])*

[VA 2017f] *Department of Veterans Affairs. What to expect before your treatment for hepatitis C virus. 2017. [Internet]. Accessed Apr 25, 2018 from <https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp> (link [<https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp>])*

[VA 2017g] *US Dept of Veterans Affairs. 2017. Taking Your Hepatitis C Therapy: Mavyret(TM). Accessed April 25, 2018. (link [<https://www.hepatitis.va.gov/products/patient/sofosbuvir-simeprevir-handouts.asp>])*

[VA 2017h] *US Dept of Veterans Affairs. 2017. Managing Side Effects of Mavyret(TM). Accessed April 25, 2018. (link [<https://www.hepatitis.va.gov/products/patient/side-effects-handouts.asp>])*

[VA 2017i] *US Dept of Veterans Affairs. 2017. Tracking My Hepatitis C Treatment Results. Accessed April 25, 2018. (link [<https://www.hepatitis.va.gov/products/patient/tracking-chart.asp>])*

[VA 2017j] *US Dept of Veterans Affairs. 2017. FAQs about Sustained Virologic Response to Treatment for Hepatitis C. Accessed April 25, 2018. (link [<https://www.hepatitis.va.gov/products/patient/sustained-virological-response.asp>])*

Supporting Evidence

[AASLD 2017] *American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated September 2017 (link [<https://doi.org/10.1002/hep.27950>])*

[Fox 2017] *Fox RK. Summary of FDA Approval for Mavyret. Published August 2017 (link [<https://www.hepatitis.va.gov/provider/hcv/mavyret-approval.asp>])*

- [VA 2017a] U.S. Department of Veterans Affairs. *After the Initial Diagnosis of HCV: Overview of Next Steps*. Published May 2017 (link [<https://www.hepatitis.va.gov/products/next-steps.asp>])
- [VA 2017b] U.S. Department of Veterans Affairs National Hepatitis C Resource Center Program and the National Viral Hepatitis Program. *Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the HIV, Hepatitis, and Related Conditions Program in the Office of Specialty Care Services*. Updated March 2017 (link [<https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp>])
- [NLM 2017a] U.S. National Library of Medicine. *HARVONI- ledipasvir and sofosbuvir tablet, film coated [Gilead Sciences, Inc]*. Updated April 2017 (link [<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075j>])
- [NLM 2017b] U.S. National Library of Medicine. *MAVYRET- glecaprevir and pibrentasvir tablet, film coated [AbbVie Inc.]*. Updated August 2017 (link [<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf99777-0401-9095-8645-16c6e907fcc0j>])
- [NLM 2016] U.S. National Library of Medicine. *REBETOL- ribavirin capsule; REBETOL- ribavirin liquid [Merck Sharp & Dohme Corp.]*. Updated January 2016 (link [<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0j>])
- [NLM 2017c] U.S. National Library of Medicine. *ZEPATIER- elbasvir and grazoprevir tablet, film coated [Merck Sharp & Dohme Corp.]*. Updated February 2017 (link [<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=164dc02a-9180-426a-b8b5-04ab39d2bbd4j>])
- [VA 2016a] VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives and Office of Public Health. *Elbasvir/Grazoprevir (Zepatier™) Criteria for Use*. Published February 2016 (link [<https://www.pbm.va.gov/apps/VANationalFormulary/>])
- [VA 2016b] VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives and Office of Public Health. *Ledipasvir/Sofosbuvir (Harvoni®) and Sofosbuvir/Velpatasvir (Epclusa®) Criteria for Use*. Published September 2016 (link [<https://www.pbm.va.gov/apps/VANationalFormulary/>])